Company Filing History:
Years Active: 2022
Title: Carolin Sellmann: Innovator in Bi-Specific Antibodies
Introduction
Carolin Sellmann is a prominent inventor based in Darmstadt, Germany. She has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative therapeutic solutions. Her work focuses on enhancing tumor selectivity and inhibition through advanced antibody technologies.
Latest Patents
Carolin Sellmann holds a patent for "Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof." This patent describes a heterodimeric bispecific immunoglobulin molecule that includes a first Fab or scFv fragment specifically binding to EGFR and a second Fab or scFv fragment binding to c-MET. The invention also features an antibody hinge region, an antibody CH2 domain, and an antibody CH3 domain, which includes a hybrid protein-protein interaction interface domain. Each interaction interface domain is formed by an amino acid segment of the CH3 domain of a first member and an amino acid segment of the CH3 domain of a second member. The hybrid protein-protein interface domain of the first chain interacts with the protein-protein interface of the second chain through homodimerization of corresponding amino acid segments.
Career Highlights
Carolin is currently employed at Merck Patent GmbH, where she continues to advance her research and development efforts in the biopharmaceutical sector. Her innovative approach and dedication to her work have positioned her as a key player in her field.
Collaborations
Carolin collaborates with notable colleagues, including Achim Doerner and Lars Toleikis, to further enhance the impact of her research and innovations.
Conclusion
Carolin Sellmann is a trailblazer in the development of bi-specific antibodies, contributing to advancements in cancer treatment. Her work exemplifies the intersection of innovation and healthcare, showcasing the potential of biopharmaceuticals in improving patient outcomes.